Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease.
Katherine E McDonellNelleke C van WouweMadaline B HarrisonScott A WylieDaniel O ClaassenPublished in: Brain and behavior (2018)
These results suggest that certain DRD polymorphisms may determine the direction of DAAg effects on critical cognitive control processes impaired in PD. Our findings have implications for understanding pharmacogenomics interactions on a larger scale and the role these may play in the wide variability of treatment effects seen in the PD population.